Amantadine and rimantadine for influenza A in children and the elderly

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Alves Galvao M G ^b   Rocha Crispino Santos, M A ^b   Alves Da Cunha, Antonio J L ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; PARACETAMOL; PLACEBO; RIMANTADINE; ZANAMIVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ALLERGIC REACTION; ANOREXIA; ANXIETY; ATAXIA; BEHAVIOR CHANGE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD CARE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELDERLY CARE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; INFECTION PREVENTION; INFLUENZA; INSOMNIA; IRRITABILITY; LIMB PAIN; MALAISE; MENTAL CONCENTRATION; MYOCLONUS; NAUSEA; OLIGOPHRENIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; TINNITUS; VOMITING; WEAKNESS; XEROSTOMIA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CYSTIC FIBROSIS; DISEASE EXACERBATION; GRAM NEGATIVE INFECTION; LUNG FUNCTION; PSEUDOMONAS AERUGINOSA; AGED; CHILD; INFLUENZA VIRUS A; META ANALYSIS; SEX DIFFERENCE;

AGED; AMANTADINE; ANTIVIRAL AGENTS; CHILD; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIMANTADINE; SEX FACTORS;

EID: 44949241618     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002745.pub2     Document Type: Review

References (188)

1. Clover 1986b {published data only} Clover RD, Crawford SA, Abell TD, Ramsey CN Jr, Glezen WP, Couch RB. Effectiveness of rimantadine prophylaxis of children within families. American Journal of Diseases of Children 1986;140 (7):706-9.
2. Clover 1991 {published data only} Clover RD, Warner JL, Becker L, Davis A. Effect of rimantadine on the immune response to influenza A infections. Journal of Medical Virology 1991;34(1):68-73. [MEDLINE: 1885945].
3. Crawford 1988 {published data only} Crawford SA, Clover RD, Abell TD, Ramsey CN, Glezen WP, Couch RB. Rimantadine prophylaxis in children: a follow up study. Pediatric infectious Disease Journal 1988;7(6):379-83.
4. Finklea 1967 {published data only} Finklea JF, Hennessy AV, Davenport FM. A field trial of amantadine prophylaxis in naturally-occurring acute respiratory illness. American Journal of Epidemiology 1967;85:403-12.
5. Gravenstein 2005 {published data only} Gravenstein S, Drinka P, Osterweil D, Schilling M, Krause P, Elliot M, et al.Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. Journal of the American Medical Directors Association 2005;6:359-66.
6. Hall 1987 {published data only} Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH, et al.Children with influenza A infeccion: treatment with rimantadine. Pediatrics 1987;80:275-82.
7. Kitamoto 1968 {published data only} Kitamoto O. Therapeutic effectiveness of amantadine hydrochloride in influenza A2-double-blind studies. The Japanese Journal of Tuberculosis and Chest Diseases 1968;15(1):17-26.
8. Kitamoto 1971 {published data only} Kitamoto O. Therapeutic effectiveness of amantadine hydrochloride in naturally occuring Hong Kong influenza - double-blind studies. The Japanese Journal of Tuberculosis and Chest Diseases 1971;17(1):1-7.
9. Monto 1995 {published data only} Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrobial Agents and Chemotherapy 1995;39:2224-8.
10. Patriarca 1984 {published data only} Patriarca PA, Kater NA, Kendal AP, Bregman DJ, Smith JD, Sikes RK. Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes. Antimicrobial Agents and Chemotherapy 1984;26(1):101-3.
11. Payler 1984 {published data only} Payler DK, Purdham PA. Influenza A prophylaxis with amantadine in a boarding school. The Lancet 1984;1(8375):502-4.
12. Schilling 1998 {published data only} Schilling M, Polvinelli L, Krause P, Gravenstein M, Ambrozaitis A, Jones HH, et al.Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771-4.
13. AAPCID 2007 American Academy of Pediatrics Committee on Infectious Diseases. Antiviral therapy and prophylaxis for inluenza in children. Pediatrics 2007;119(4):852-60.
14. Allen 2006 Allen UD, Aoki FY, Stiver HG. The use of antiviral drugs for influenza: recommended guidelines for practioners. The Canadian Journal of infectious Diseases and Medical Microbiology 2006;17(5): 273-84.
15. Anonymous 2006 Anonymous. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire International 2006;15(81):21-30.
16. Anonymous 2007 Anonymous. Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best. Prescrire International 2007;16 (87):9-11.
17. Aoky 1985a Aoky FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clinical pharmacology and therapeutics 1985;37(2):137-4.
18. Aoky 1985b Aoky FY, Silver HG, Sitar DS, Boudreault A, Ogilvie RI. Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults. Clinical Pharmacology and Therapeutics 1985;37(2):128-36.
19. Aoky 1986 Aoky FY, Sitar DS, Milley EV. Potential of influenza vaccine and amantadine to prevent influenza A illness in Canadian Forces personnel 1980-1983. Military Medicine 1986;151(9):459-65.
20. Atmar 1990 Atmar RL, Greenberg SB, Quarles JM, Wilson SZ, Tyler B, Feldman S, et al.Safety and pharmacokinetics of rimantadine small-particle aerosol. Antimicrobial agents and chemotherapy 1990;34(11):2228- 33.
21. Baker 1969 Baker LM, Shock MP, Iezzoni DG. The therapeutic efficacy of Symmetrel (amantadine hydrochloride) in naturally occuring influenza A2 respiratory illness. The Journal of the American Osteopathic Association 1969;68(12):1244-50.
22. Barr 2007 Barr IG, Hurt AC, Deed N, Iannello P, Tomasov C, Komadina N. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Research 2007;75(2):173-6.
23. Barr 2007b Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Research 2007;73(2):112-7.
24. Bauer 2007 Bauer K, Schrader C, Suess J, Wutzler P, Schmidtke M. Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999. Antiviral Research 2007;75(3):219-26.
25. Belenky 1998 Belenky S, Gentile D, Doyle W, Patel A, Hayden F, Skoner D. Rimantadine effect on specific serum hemagglutination inhibition and nasal antibodies in experimental influenza virus exposure of adults. American Journal of Respiratory and Critical Care Medicine 1998;157(3):A173.
26. Bloomfield 1970 Bloomfield SS, Gaffney TE, Schiff GM. A design for the evaluation of antiviral drugs in human influenza. American Journal of Epidemiology 1970;91(6):568-74.
27. Brady 1990 Brady MT, Sears SD, Pacini DL, Samorodin R, DePamphilis J, Oakes M, et al.Safety and prophylatic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrobial Agents and Chemotherapy 1990;34(9):1633-6.
28. Bricaire 1990 Bricaire F, Hannoun C, Boissel JP. Prevention of influenza A. Effectiveness and tolerance of rimantadine hydrochloride [Prevention de la grippe A. Efficacite et tolerance du chlohydrate de rimantadine]. Nouvelle Presse Médicale 1990;19(2):69-72.
29. Bryson 1990 Bryson YJ, Monahan C, Pollack M, Shields WD. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. The Journal of Infectious Diseases 1980;141:543-7.
30. Callmander 1968 Callmander E, Hellgren L. Amantadine hydrochloride as a prophylatic in respiratoty infections. A double-blind investigation of its clinical use and serology. The Journal of Clinical Pharmacology and The Journal of New Drugs 1968;8(3):186-9.
31. Chemaly 2006 Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ el al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85(5): 278-87.
32. Cheng 2004 Cheng VCC, Tang BSF, Wu AKL, Chu CM, Yuen KY. Medical treatment of viral pneumonia including SARS in immunocompetent adult. The Journal of Infection 2004;49(4):262-73. [MEDLINE: 2004434613].
33. Cohen 1976 Cohen A, Togo Y, Khakoo R, Waldman R, Sigel M. Comparative clinical and laboratory evaluation of the prophylatic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. The Journal of Infectious Diseases 1976;133(Suppl):A114-20.
34. Cohen 2006 Cohen J, Cairns C, Paquette C, Faden L. Compairing patient access to pharmaceuticals in the UK and US. Applied Health Economics and Health Policy 2006;5(3):177-87.
35. Dawkins 1968 Dawkins AT Jr, Gallager LR, Togo Y, Hornick RB, Harris BA. Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analoge of amantadine hydrochloride. Journal of the American Medical Association 1968;203:1095-9.
36. Denys 1963 Denys A, Szram S, Tkaczewski W, Niedzielska H, Bochenska J, Kulawczyk M, et al.Antiviral activity of rimantadine, virological, pathomorphological, and clinical studies. Acta Microbiologica Polonica. Series A: Microbiologia Generalis 1973;5:217-20.
37. Dolamore 2003 Dolamore MJ. Influenza prophylaxis in long-tern care facility: a case-control study of the risk factors for adverse drug reactions to amantadine. Current Therapeutic Research, Clinical and Experimental 2003;64(9):753. [MEDLINE: 2004048279].
38. Dolin 1982 Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. The New England Journal of Medicine 1982;307(10):580-4.
39. Doyle 1998 Doyle WJ, Skoner DP, Patel A, Hayden FG. Effect of rimantadine on induced specific serum haemagglutination-inhibiting antibody and nasal IgA titres after experimental exposure of adults to influenza A virus. Antiviral Therapy 1998;3(1):19-23.
40. Drinevskii 1998 Drinevskii VP, Osidak LV, Natsina VK, Afanas'eva OI, Mil'kint KK, Danini GV, et al.Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children [Khimiopreparaty v terapii grippa i drugikh respiratomykh infektsii u detei]. Antibiotiki i Khimioterapiia 1998;43(9):29-34.
41. Drinka 1998 Drinka PJ, Gravenstein S, Schilling M, Krause P, Miller BA, Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza.A comparison of 2 protocols. Archives of Internal Medicicine 1998;158(19):2155-9.
42. Enger 2004 Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiology and Drug Safety 2004;13(4):227-37. [MEDLINE: 2004179080].
43. Furuta 2005 *Furuta Y, Takahashi K, Kuno-Markawa M, Sangawa H, Uehara S, Kozaki K el al. Mechanism of action of T-705 against influenza virus. Antimicrobial Agents and Chemotherapy 2005;49(3):981-6.
44. Galabov 2006 Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antiviral Chemistry & Chemotherapy 2006;17(5):251-8.
45. Galbraith 1969a Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 1969;2 (7629):1026-8.
46. Galbraith 1969b Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1-adamantanamine hydrochloride used prophylatically during the Hong-Kong influenza epidemic in the family environment. Bulletin of the World Health Organization 1969;41(3):677-82.
47. Galbraith 1971 Galbraith AW, Oxford JS, Schild GC, Potter CW, Watson GI. Therapeutic effect of 1-adamantanamine hydrochloride in naturally occuring influenza A 2-Hong Kong infection. A controlled double-blind study. Lancet 1971;2(7716):113-5.
48. Galbraith 1973 Galbraith AW, Schild GC, Potter CW, Watson GI. The therapeutic effect of amantadine in influenza occurring during the winter of 1971-2 assessed by double-blind study.The Journal of the Royal College of General Practitioners 1973;23(126):34-7.
49. Garman 2004 Garman E, Laver G. Controlling influenza by inhibiting the virus's neuramidase. Lancet 2004;363(9409):617-9. [MEDLINE: 2004098284].
50. Gerth 1966 Gerth, HJ. Influenza prevention with 1-amino-adamantan-hydrochloride. II [Grippeprophylaxe mit 1-Amino-adamantan- hydrochlorid]. Die Medizinische Welt 1966;2:96-100.
51. Griffin 2004 Griffin SDC, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ. A conserved basic loop in hepatites C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization tomitochondria. The Journal of General Virology 2004;85(2):451-61. [MEDLINE: 2004096848].
52. Hay 1986 Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. The Journal of Antimicrobial Chemotherapy 1986;18:19-29.
53. Hayden 1979 Hayden FG, Hall WJ, Douglas RGJ, Speers DM. Amantadine aerosols in normal volunteers; pharmacology and safety testing. Antimicrobial Agents and Chemotherapy 1979;16(5):644-50.
54. Hayden 1980 Hayden FG, Hall WJ, Douglas FG Jr. Therapeutic effects of aerolized amantadine in naturally acquired infection due to influenza A virus. The Journal of Infectious Diseases 1980;141(5):535-42.
55. Hayden 1981 Hayden FG, Gwaltney JM Jr, Van de Castle RL, Adams KF, Giordani F. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrobial Agents and Chemotherapy 1981;19(2):226-33.
56. Hayden 1982 Hayden FG, Zylidnikov DM, Iljenko VI, Padolka YV. Comparative therapeutic effect of aerolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Research 1982;2(3):147-53.
57. Hayden 1985 Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrobial Agents and Chemotherapy 1985;28(2):216-21.
58. Hayden 1986 Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrobial Agents and Chemotherapy 1986;29(2):339-41.
59. Hayden 1989 Hayden FG, Belshe RB, Clover RB, Hay AJ, Oakes MG, Soo W. Emergence and and aparent transmission of rimantadine-resistant influenza A virus in families. The New England Journal of Medicine 1989;321(25):1696-702.
60. Hayden 1991 Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrobial Agents and Chemotherapy 1991;35:1741-7.
61. Hayden 2000 Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM, et al.Inhaled zanamivir for the prevention of influenza in families. The New England Journal of Medicine 2000;343(18):1282-9.
62. Hayden 2006 Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. The Journal of Infectious Diseases 2006;194(Suppl 2):155-61.
63. Hornick 1969 Hornick RB, Togo Y, Mahler S, Iezzoni D. Evaluation of amantadine hydrochloride in the treatment of A2 influenzal disease. Bulletin of the World Health Organization 1969;41(3):671-6.
64. Hout 2006 Hout DR, Gomez LM, Pacyniak E, Miller JM, Hill MS, Stephens EB. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine. Virology 2006;348(2):449-61.
65. Hout 2006b Hout DR, Gomez ML, Pacyniak E, Gomez LM, Fegley B, Mulcahy ER el al. Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques. Virology 2006;344(2):541- 59.
66. Hurt 2007 Hurt AC, Selleck P, Komadina S, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 2007;73(3):228-31.
67. Ilyushina 2005 Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 2005;341(1):102-6.
68. Ilyushina 2006 IIyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Research 2006;70(3):121-31.
69. Ilyushina 2007 Ilyushina NA, Gorkova EA, Russell CJ, Hoffmann E, Webster RG. Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. The Journal of General Virology 2007;88(4):1266-74.
70. Ilyushina 2007b Ilyushina NA, Hoffmann E, Solomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Therapy 2007;12(3):363-70.
71. Ison 2006 Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. The Journal of Infectious Diseases 2006;193(6):760-4.
72. Ito 2000 Ito S, Iijima N, Kanemaki K, Hayashi S, Hujii S, Watanabe T, et al.Therapeutic efficacy of amantadine hydrochloride in patients with epidemic influenza A virus infection. Nihon Kokyuki Gakkai Zasshi [The journal of the Japanese Respiratory Society] 2000;38(12):897-902.
73. Ito 2006 Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health care workers, using rapid antigen detection test. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy 2006;12(2):70-2.
74. Jefferson 2004 Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in in adults. Cochrane Database of Systematic Reviews 2004, Issue 3.
75. Jefferson 2006a Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367(9507):303-13.
76. Jones 2006 Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. Journal of Virology 2006;80(24):11960-7.
77. Kantor 1980 Kantor RJ, Stevens D, Potts DW, Noble GR. Prevention of influenza A/USSR/77 (H1N1): an evaluation of the side effects and efficacy of amantadine in recruits at Fort Sam Houston. Military Medicine 1980;145(5):312-5.
78. Kawai 2005 Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T, et al.Factors influencing the effects of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 2005;40:1309-16.
79. Khakoo 1981 Khakoo RA, Watson GW, Waldman RH, Ganguly R. Effect of inosiplex (Isoprinosine (Reg. trademark)) on induced human influenza A infection. The Journal of Antimicrobial Chemotherapy 1981;7(4): 389-97.
80. Kiso 2004 Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al.Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364(9436):759-65. [MEDLINE: 2004375940].
81. Kitamoto 1969 Kitamoto O. Early diagnosis and treatment of influenza. Naika. Internal medicine 1969;23(6):1271-6.
82. Knight 1969 Knight V, Fedson D, Baldini J, Douglas RG, Couch RB. Amantadine therapy of epidemic influenza A2-Hong Kong. Antimicrobial Agents and Chemotherapy 1969;9:370-1.
83. Knight 1970a Knight V, Fedson D, Baldini J, Douglas R, Couch R. Amantadine therapy of epidemic influenza A (Hong Kong). Infection and Immunity 1970;1:200-4.
84. Knight 1970b Knight V, Fedson D, Baldini J, Douglas R, Couch R. Amantadine therapy of epidemic influenza A (Hong Kong). Infection and Immunity 1970;1:200-4.
85. Knight 1981 Knight V, McClung HW, Wilson SZ, Waters BK, Quarles JM, Cameron RW, et al.Ribavirin small-particle aerosol treatment of influenza. Lancet 1981;2(8253):945-9.
86. Krylov 1978 Krylov VF, Ketilladze ES, Smagulova EG, Alekseeva AA, Nefelova MM. Use of rimantadine in familial foci during an epidemic of influenza caused by A1 virus [Primenenie rimantadina v semeinykh ochagakh v period epidemii grippa, vyzvannogo virusom A1]. Voprosy Virusologii 1978;3:277-82.
87. Kulichenko 2003 Kulichenko LL, Kireyeva LV, Malyshikina EN, Wikman G. A randomized controlled study of Kan Jang versus amantadine in the treatment of influenza in Volgograd. Journal of Erbal Pharmacotherapy 2003;3(1):77-93.
88. Le Tissier 2005 LeTissier PR, Carmignac DF, Lilley S, Sesay AK, Phelps CJ, Houston P, et al. Hypothalamic growth hormone-releasing hormone (GHRH) defiency: target ablation pf GHRH neurons in mice using a viral ion channel transgene. Molecular Endocrinology 2005;19(5):1251-62.
89. Leeming 1969 Leeming JT. Amantadine hydrochloride and the elderly. British Medical Journal 1969;1(639):313-4.
90. Leone 2005 Leone H, Polsonetti BW. Amantadine for traumatic brain injury: does it improve cognition and reduce agitation?. Journal of Clinical Pharmacy and Therapeutics 2005;30(2):101-4.
91. Leung 1979 Leung P, McIntosh K, Chai H. Amantadine prophylaxis against influenza A/USSR in children with chronic asthma. The Journal of Allergy and Clinical Immunology 1979;63(3):140.
92. Lim 2007 Lim WS. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Thorax 2007;62 (Suppl 1):1-46.
93. Lin 2006 Lin CH, Huang YC, Chi CH, Huang CG, Tsao KC, Lin TY. Neurologic manifestations in children with influenza B virus infection. The Pediatric Infectious Disease Journal 2006;25(11):1081-3.
94. Linder 2005 Linder JA, Bates DW, Platt R. Antivirals and antibiotics for influenza in the United States, 1995-2002. Pharmacoepidemiology and Drug Safety 2005;14(8):531-6.
95. Lipatov 2007 Lipatov AS, Evseenko VA, Yen HL, Zaykovskaya AV, Durimanov AG, Zolotykh SI, et al.Influenza (H5N1) viruses in poultry, Russian Federation, 2005-2006. Emerging Infectious Diseases 2007;13(4): 539-46.
96. Little 1976 Little JW, Hall WJ, Douglas RG Jr, Hyde RW, Speers DM. Amantadine effect on peripheral airways abnormalities in influenza A study in 15 students with natural influenza A infection. Annals of Internal Medicine 1976;85(2):177-82.
97. Little 1978 Little JW, Hall WJ, Douglas RG Jr, Mudholkar GS, Speer DM, Patel K. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. The American Review of Respiratory Disease 1978;118(2):295-303.
98. Lutz 2005 Lutz A, Dyall J, Olivo PD, Pekosz A. Virus-inducible reporter genes as a tool for detecting and quantifying influenza A virus replication. Journal of Virological Methods 2005;126(1-2):13-20.
99. Lynd 2005 Lynd LD, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmaco Economics 2005;23(11):1083-106.
100. Machado 2004 Machado CM, Boas LSV, Mendes AVA, da Rocha IF, Sturaro D, Dulley FL, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplantation 2004;34(2):111-4. [MEDLINE: 2004347904].
101. Mallia 2007 Mallia P, Johnston SL. Influenza infection and COPD. International Journal of Chronic Obstructive Pulmonary Disease 2007;2(1):55-64.
102. Maricich 2004 Maricich SM, Neul JL, Lotze TE, Cazacu AC, Uyeki TM, Demmler GJ, et al.Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in Houston, Texas. Pediatrics 2004;114(5):626-33.
103. Mase 2007 Mase M, Eto M, Imai K, Tsukamoto K, Yamaguchi S. Caracterization of H9N2 influenza A viruses isolated from chicken products imported into Japan from China. Epidemiology and Infection 2007;135(3):386-91.
104. Mate 1970 Mate J, Simon M, Juvancz I, Takatsy G, Hollos I, Farkas E. Prophylatic use of amantadine during Hong Kong influenza epidemic. Acta Microbiologica Academiae Scientiarum Hungaricae 1970;17(3):285-96.
105. Mate 1971 Mate J, Simon M, Juvancz I. Use of Viregyt (amantadine hydrochloride) in the treatment of epidemic influenza. Therapia Hungarica 1971;19(3):117-21.
106. Matsuya 2007 Matsuya Y, Sasaki K, Ochiai H, Nemoto H. Synthesis and biological evaluation of dihydrofuran-fused perhydrophenanthrenes as a new anti-influenza agent having novel structural characteristic. Bioorganic & Medicinal Chemistry 2007;15(1):424-32.
107. Matthews 2004 Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clinical Therapeutics 2004;26(7):991-1025. [MEDLINE: 2004369381].
108. McCullers 2004 McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. The Journal of Infectious Diseases 2004;190(3):519-26. [MEDLINE: 2004322950].
109. McKay 2006 McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC. Influenza M2 envelope protein augments avian influeza hemagglutinin pseudotyping of lentiviral vectors. Gene Therapy 2006;13(8):715-24.
110. Mishin 2005 Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrobial Agents and Chemotherapy 2005;49(11):4515-20.
111. Monto 1979 Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. Journal of the American Medical Association 1979;241(10):1003-7.
112. Muldoon 1976 Muldoon RL, Stanley ED, Jackson GG. Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A. The American Review of Respiratory Disease 1976;113:487-91.
113. Nafta 1970 Nafta I, TTurcanu AG, Braun I, Companetz W, Simionescu A. Administration of amantadine for the prevention of Hong-Kong influenza. Bulletin of the World Health Organization 1970;42(3):200-4.
114. Natsina 1994 Natsina VK, Drinevskii VP, Milkint KK. Remantadine in the treatment of influenza in children [Primenenie remantadina dlia lecheniia grippa u detei]. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk Vestnik 1994;9:51-5.
115. O'Donoghute 1973 O'Donoghute JM, Ray CG, Terry DW Jr, Beaty HN. Prevention of nosomial influenza infection with amantadine. American Journal of Epidemiology 1973;97(4):276-82.
116. Obrosova-Serova 1972 Obrosova-Serova NP, Fedorova GI, Glukhov PI, Shal'nov MI, Litvinov VG. Effectiveness of midantan and interferon inducers as means og non-specific prevention of influenza [Izuchenie effektivnosti midantana i stimuliatorav interferona kak sredstv nespetsificheskoi profilaktiki grippa]. Antibiotiki 1972;17:734-8.
117. Oker-Blom 1970 Oker-Blom N, Hovi T, Leinikki P, Palosuo T, Petterson R, Suni J. Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial. British Medical Journal 1970;3(724):676-8.
118. Ong 2007 Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. The Journal of Infectious Diseases 2007;196(2):181-90.
119. Pachucki 2004 Pachucki CT, Kurshid MA, Nawrocki J. Utility of reverse transcriptase PCR for rapid diagnosis of influenza A virus infection and detection of amantadine-resistant influenza A virus isolates. Journal of Clinical Microbiology 2004;42(6):2796-8. [MEDLINE: 2004251487].
120. Peiris 2004 Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al.Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004;21(363):617-9.
121. Pemberton 1986 Pemberton RM, Jennings R, Potter CW, Oxford JS. Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates. The Journal of Antimicrobial Chemotherapy 1986;18:135-40.
122. Petterson 1980 Petterson RF, Hellstrom PE, Penttinen K, Pyhala R, Tokola O, Vartio T, et al.Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients. The Journal of Infectious Diseases 1980;142 (3):377-83.
123. Pritchard 1989 Pritchard MH, Munro J. Successful treatment of juvenile chronic arthritis with a specific antiviral agent. British Journal of Rheumatology 1989;28(6):521-4.
124. Quarles 1981 Quarles JM, Couch RB, Cate TR, Goswick CB. Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza. Antiviral Research 1981;1(3):149-55.
125. Quilligan 1966 Quilligan JJ Jr, Hirayama H, Baernstein HD Jr. The suppression of A2 influenza in children by the chemoprophylatic use of amantadine. The Journal of Pediatrics 1966;69(4):572-5.
126. Rabinovich 1969 Rabinovich S, Baldini JT, Bannister R. Treatment of influenza. The therapeutic efficacy of rimantadine HCl in a naturally occurring influenza A2 outbreak. The American Journal of the Medical Sciences 1969;257(5):328-35.
127. Reis 2006 Reis J, John D, Heimeroth A, Mueller HH, Oertel WH, Arndt T, et al.Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 2006;31(12):2758-66.
128. Reuman 1989a Reuman PD, Bernstein DI, Keely SP, Young EC, Sherwood, JR, Schiff GM. Differential effect of amantadine hydrochloride on systemic and local immune response to influenza A. Journal of Medical Virology 1989;27(2):137-41.
129. Reuman 1989b Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Research 1989;11(1):27-40.
130. Risebrough 2005 Risenbrough NA, Bowles SK, Simor AE, McGeer A, Oh PI. economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. Journal of the American Geriatrics Society 2005;53(3):444-51.
131. Rose 1980 Rose HJ. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. The Journal of Infectious Diseases 1980;141(5):535-42.
132. Rothberg 2005 Rothberg MB, Fisher D, Kelly B, Rose DN. Management of influenza symptoms in healthy children. Archives of pediatrics & adolescent medicine 2005;159:1055-62.
133. Saito 2006 Saito R, Li D, Shimomura C, Masaki H, Le MR, Nquyen HL, et al.An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan. The Tohoku Journal of Experimental Medicine 2006;210(1):21-7.
134. Sauerbrei 2006 Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P. Utilization of the embryonated egg for in vivo evaluation of the antiinfluenza virus activity of neuraminidase inhibitors. Medical Microbiology and Immunology 2006;195(2):65-71.
135. Schapira 1971 Schapira M, Oxford JS, Galbraith AW. Therapeutic effect of 1-adamantanamine hydrochloride in naturally. Journal of the Royal College of General Practitioners 1971;21(113):695-7.
136. Schmidt 2004 Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004;64(18):2031- 46. [MEDLINE: 2004412233].
137. Sears 1987 Sears SD, Clements ML. Protective efficacy of low dose amantadine in adults challenge with wild-type influenza A virus. Antimicrobial Agents and Chemotherapy 1987;31(10):1470-3.
138. Semlitsch 1992 Semlitsch HV, Anderer P, Saletu B. Topographic mapping of long latency "cognitive"event-related potentials (P 300): a double-blind, placebo-controlled study with amantadine inmild dementia. Journal of Neural Transmission. Parkinson's disease and dementia section 1992;4:319-36.
139. Serkedjieva 2007 Serkedjieva J, Toshkova R, Antonova-Nikolova S, Stefanova T, Teodosieva A, Ivanova I. Effect of a plant polyphenol-rich extract on the lung protease activities of influenza-virus-infected mice. Antiviral Chemistry & Chemotherapy 2007;18(2):75-82.
140. Shuler 2007 Schuler CM, Iwamoto M, Bridges CB, Marin M, Neeman R, Gargiullo P, et al.Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics 2007;119(3):587-95.
141. Shvetsova 1974 Shvetsova EG, Malysheva AM, Karapats NM, Oleinikova EV, Vasil'eva RI. Comparative study of the epidemiological efficacy of specific
142. Skoner 1999 Skoner DP, Gentile DA, Patel A, Doyle WJ. Evidence for cytokine mediation of disease exression in adults experimentally infected with influenza A virus. The Journal of Infectious Diseases 1999;180(1):10-4.
143. Smorodintsev 1970a Smorodintsev AA, Zlydnikov DM, Kiselva AM, Romanov JA, Kanantsev AP, Rumovsky VI. Evaluation of amatadine in artificially induced A2 and B influenza. JAMA : the journal of the American Medical Association 1970;213(9):1448-54.
144. Smorodintsev 1970b Smorodintsev AA, Karpuhin GI, Zlydnikov DM, Malyseva AM, Svecova EG, Burov SA, et al.The prophylatic effectiveness of amantadine hydrochloride in an epidemic of Hong Kong influenza in Leningrad in 1969. Bulletin of the World Health Organization 1970;42(6):865-72.
145. Smorodintsev 1970c Smorodintsev AA, Karpuhin GI, Zlydnikov DM. The prospect of amantadine for prevention of influenza A in humans (effectiveness of amantadine during influenza A2/Hong Kong epidemics in January-February 1969 in Leningrad. Annals of the New York Academy of Sciences 1970;173:44-73.
146. Somani 1991 Somani SK, Degelau J, Cooper SL, Guay DRP, Ehresman D, Zaske D. Comparision of pharmacokinetic and safety profiles of amantadine 50 and 100 mg daily doses in elderly nursing home residents. Pharmacotherapy 1991;11(6):440-66.
147. Tajima 2006 Tajima T, Kakayama E, Kondo Y, Hirai F, Ito H, Iitsuka T, et al.Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2006;12(6):372-9.
148. Takemura 2005 Takemura Y, Ishida H, Saitoh H, Kure H, Kakoi H, Ebisawa K, et al.Economic consequence of immediate testing for C-reactive protein and leukocyte count in new outpatients with acute infection. Clinica Chimica Acta; International Journal of Clinical Chemistry 2005;360 (1-2):114-21.
149. Terabayashi 2006 Terabayashi T, Morita M, Ueno M, Nakamura T, Urashima T. Inhibition of influenza-virus-induced cytopathy by sialylglycoconjugates. Carbohydrate Research 341;13:2246-53.
150. Thompson 1987 Thompson J, Fleet W, Lawrence E, Pierce E, Morris L, Wright P. A comparision of acetaminophen and rimantadine in the treatment of influenza A infection in children. Journal of Medical Virology 1987;21(3):249-55.
151. Togo 1968 Togo Y, Hornick RB, Dawkins AT Jr. Studies on induced influenza in man. I. Double-blind studies designed to assess prophylatic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain. Journal of the American Medical Association 1968;203(13):1089-94.
152. Togo 1970 Togo Y, Hornick RB, Felitti VJ, Kaufman ML, Dawkins AT Jr, Kilpe VE, et al.Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. Journal of the American Medical Association 1970;211(7):1149-56.
153. Togo 1972 Togo Y, Schwatrz AR, Tominaga S, Hornick RB. Cyclooctylamine in the prevention of experimental human influenza. Journal of the American Medical Association 1972;220(6):837-41.
154. Townsend 2006 Townsend KA, Eiland LS. Combating influenza with antiviral therapy in the pediatric population. Pharmacotherapy 2006;26(1):95-103.
155. van der Wouden 2005 van der Wouden JC, Bueving HJ, Poole P. Preventing influenza: an overview of systematic reviews. Respiratory Medicine 2005;99(11):1341-9.
156. Van Voris 1981 Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr. Successful treatment of naturally occuring influenza A/USSR/77 H1N1. Journal of the American Medical Association 1981;245(11): 1128-31.
157. Van Voris 1985 Van Voris LP, Betts RF, Menegus MA, Murphy BR, Roth FK, Douglas RG Jr. Serological diagnosis of influenza A/USSR/77 H1N1 infection: value of ELISA compared to other antibody techniques. Journal of Medical Virology 1985;16(4):315-20.
158. Webster 1986 Webster R, Kawaoka Y, Bean W. Vaccination as strategy to reduce the emergence of amantadine and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus. The Journal of Antimicrobial Chemotherapy 1986;18:157-64.
159. Wendel 1966 Wendel HA, Snyder MT, Pell P. Trial of amantadine in epidemic in influenza. Clinical Pharmacology and Therapeutics 1966;7(1):38-43.
160. Wingfield 1969 Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occuring influenza A2 respiratoty illness in man. The New England Journal of Medicine 1969;281(11):579-84.
161. Wong 2006 Wong SS, Yuen KY. Avianinfluenza virus infections in humans. Chest 2006;129(1):156-68.
162. Wright 1976 Wright PF, Khaw KT, Oxman MN, Shwachman H. Evaluation of the safety of amantadine-HCL and the role of respiartory viral infections in children with cystic fibrosis. The Journal of Infectious Diseases 1976;134(2):144-9.
163. Wultzler 2004 Wultzler P, Kossow KD, Lode H, Ruf BR, Scholz H, Vogel GE, et al.Antiviral treatment and prophylaxis of influenza in primary care: German recommendations. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2004;31(2):84-91.
164. Yamaura 2003 Yamaura K, Yoshihara M. Investigation of the reconsultation rate and pharmacoeconomic evaluation of period of influenza treatment by oseltamivir. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2003;123(10):887-91.
165. Younkin 1983 Younkin SW, Betts RF, Roth FK, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrobial Agents and Chemotherapy 1983;23(4):577-82.
166. Yuen 2005 Yuen KY, Wong SS. Human infection by avian influenza A H5N1. Hong Kong Medical Journal 2005;11(3):189-99
167. Zeuzem 1999 Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, et al.Randomised, double-blind, placebo-controlled trial of interferonalfa with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 1999;30(4):200A.
168. Bonn 1997 Bonn D. Spared an influenza pandemic for another year?. Lancet 1997;349(9044):36.
169. Demicheli 2000 Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in health adults. Vaccine 2000;18:957-1030.
170. Dolin 2005 Dolin R. Influenza-interpandemic as well as pandemic disease. New England Journal of Medicine 2005;353(24):2535-7.
171. Eccle 2005 Eccle R. Understanding the symptoms of the common cold and influenza. The Lancet Infectious Diseases 2005;5:718-25.
172. Goodman 2006 Goodman C, Mukherjee D, Faulkner E. How effective would antiviral vaccination and antiviral drug prevention and treatment strategies be for reducing the impact of the next influenza pandemic. Copenhagen, WHO Regional Office for Europe (Health Evidence Network report; http://www.euro.who.int/Document/E88034.pdf (Accessed October 20, 2007) 2006.
173. Hayden 2004 Hayden FG. Pandemic influenza: is an antiviral response realistic?. Pediatric Infectious Disease Journal 2004;23(Suppl):262-9.
174. Hayden 2005 Hayden FG, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, et al.Neuraminidase inhibitor susceptibility network position statment: antiviral resistance in influenza A/H5N1 viruses. Antiviral Therapy 2005;10(8):873-7.
175. Hayden 2006b Hayden FG. Antiviral resistance in influenza viruses - implications for management and pandemic response. New England Journal of Medicine 2006;354(8):785-8.
176. Higgins 2005 Higgins JPT, Green S, editors. Developing and documenting a search strategy for studies and organizing search results. Cochrane Handbook for Systematic Reviews of Interventions 4.2 [updated May 2005]; Section 5. In: The Cochrane Library. Vol. Issue 3, Chichester, UK: John Wiley & Sons, Ltd, 2005.
177. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
178. Jefferson 2006b Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database of Systematic Reviews 2006, Issue 2.
179. Moscona 2005 Moscona A. Neuraminidase inhibitors for Influenza. New England Journal of Medicine 2005;353:1363-73.
180. MS 2006 Ministério da Saúde 2006 (Brazilian Ministry of Health 2006). Human influenza and avian influenza [Influenza humana e influenza aviária]. Série F. Comunicação e Educação em Saúde 2006.
181. Nicholson 1992 Nicholson K. Clinical featuresof influenza. Seminars in Respiratory Infections 1992;7(1):26-37.
182. Pineda Solas 2006 Pineda Solas A, Bernaola Iturbe E, Martinon-Torres F, Baca Cots M, de Juan Martin F, Gomez Campdera JA, et al.Recommendations of the Vaccine Advisory Committee of the Spanish Association of Pediatrics: influenza vaccination campaign 2006-2007. Anales de Pediatría 2006;65(3):252-5.
183. Smith 2006 Smith NM, Bresee JJ, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 2006;55(RR10):1-42.
184. Treanor 2005 Treanor JJ. Influenza Viruses. In: Mandell, Bennett, & Dolin editor (s). Principles and Practice of Infectious Diseases. 6th Edition. Vol. 2, W. B. Saunders, an imprint of Elsevier, 2005:2060-85.
185. WHO 2003 World Health Organization. Influenza. Geneva, World Health Organization, 2003 (Fact Sheet No. 211). http://www.who.int/mediacentre/ factsheets/fs211/en/print.html (Accessed October 20, 2007) 2003.
186. WHO 2007 World Health Organization. Child and adolescent health and development. http://www.who.int/child-adolescent-health/over.htm (Accessed January 20, 2007).
187. Wiselka 1994 Wiselka M. Influenza: diagnosis, management and prophylaxis. BMJ 1994;308:1341-5.
188. Wright 2004 Wright P. Influenza Viruses. In: RichardE Behrman, RobertM Kliegman, HallB Jenson editor(s). Nelson Textbook of Pediatrics of Pediatrics. 17. Saunders, An Imprint of Elsevier, 2004:1072-5.